Patents by Inventor Morgan L. Maeder

Morgan L. Maeder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING SICKLE CELL DISEASE
    Publication number: 20230026726
    Abstract: CRISPR/CAS-related compositions and methods for treatment of Sickle Cell Disease (SCD) are disclosed.
    Type: Application
    Filed: February 7, 2022
    Publication date: January 26, 2023
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Ari E. FRIEDLAND, Morgan L. MAEDER, G. Grant WELSTEAD, David A. BUMCROT
  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING USHER SYNDROME AND RETINITIS PIGMENTOSA
    Publication number: 20220135970
    Abstract: CRISPR/Cas-related compositions and methods for treatment of Usher Syndrome and/or Retinitis Pigmentosa are disclosed herein.
    Type: Application
    Filed: June 7, 2021
    Publication date: May 5, 2022
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Morgan L. MAEDER, David A. BUMCROT
  • CRISPR-CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS FOR CANCER IMMUNOTHERAPY
    Publication number: 20220106600
    Abstract: CRISPR/CAS-related compositions and methods for treatment of cancer.
    Type: Application
    Filed: August 26, 2021
    Publication date: April 7, 2022
    Inventors: G. Grant Welstead, Ari E. Friedland, Morgan L. Maeder, David A. Bumcrot
  • CRISPR/CAS-related methods and compositions for treating sickle cell disease
    Patent number: 11242525
    Abstract: CRISPR/CAS-related compositions and methods for treatment of Sickle Cell Disease (SCD) are disclosed.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: February 8, 2022
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Ari E. Friedland, Morgan L. Maeder, G. Grant Welstead, David A. Bumcrot
  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING CYSTIC FIBROSIS
    Publication number: 20210380987
    Abstract: CRISPR/CAS-related compositions and methods for treatment of Cystic Fibrosis (CF).
    Type: Application
    Filed: April 30, 2021
    Publication date: December 9, 2021
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Deepak Reyon, Morgan L. Maeder, Ari E. Friedland, G. Grant Welstead, David A. Bumcrot
  • CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa
    Patent number: 11028388
    Abstract: CRISPR/Cas-related compositions and methods for treatment of Usher Syndrome and/or Retinitis Pigmentosa are disclosed herein.
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: June 8, 2021
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Morgan L. Maeder, David A. Bumcrot
  • CRISPR/CAS-related methods and compositions for treating cystic fibrosis
    Patent number: 11028394
    Abstract: Disclosed herein are genome editing systems and compositions that target a cystic fibrosis transmembrane conductance regulator (CFTR) gene and a sodium channel epithelial 1 alpha (SCNN1A) gene, comprising a Cas9 molecule, and a gRNA molecule comprising a targeting domain that is complementary with a target sequence of a CFTR gene or a SCNN1A gene, and cells comprising such genome editing systems and compositions. Also provided are methods for using the genome editing systems, compositions, and cells for genome engineering (e.g., altering a CFTR gene and/or a SCNN1A gene), and for preventing or treating Cystic Fibrosis (CF) and CF-like disease.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: June 8, 2021
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Deepak Reyon, Morgan L. Maeder, Ari E. Friedland, G. Grant Welstead, David A. Bumcrot
  • CRISPR/Cas9-Mediated Exon-Skipping Approach for USH2A-Associated Usher Syndrome
    Publication number: 20210115419
    Abstract: Compositions for use in treating subjects with USH2A-associated retinal and/or cochlear degeneration that result from mutations in exon 13 of the USH2A gene by deletion of exon 13 from the USH2A gene or transcripts, and methods of use thereof, as well as genetically modified animals and cells.
    Type: Application
    Filed: March 25, 2019
    Publication date: April 22, 2021
    Inventors: Eric A. Pierce, Carrie Marie Margulies, Nachiket D. Pendse, Sebastian W. Gloskowski, Liu Qin, Morgan L. Maeder
  • GENETICALLY ENGINEERED CELLS AND METHODS OF MAKING THE SAME
    Publication number: 20190136230
    Abstract: Provided are CRIS PR/CAS-related methods, compositions and components for editing a target nucleic acid sequence, or modulating expression of a target nucleic acid sequence, and applications thereof in connection with cancer immunotherapy comprising adoptive transfer of engineered T cells or T cell precursors.
    Type: Application
    Filed: May 6, 2017
    Publication date: May 9, 2019
    Applicants: Juno Therapeutics, Inc., Editas Medicine, Inc.
    Inventors: Blythe SATHER, G. Grant WELSTEAD, David A. BUMCROT, Ari E. FRIEDLAND, Jon JONES, Morgan L. MAEDER, Chris NYE, Eugenio Marco RUBIO, Ruth SALMON
  • CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10)
    Patent number: 9938521
    Abstract: CRISPR/CAS-related compositions and methods for treatment of Leber's Congenital Amaurosis 10 (LCA10) are disclosed.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: April 10, 2018
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Morgan L. Maeder, David A. Bumcrot, Shen Shen
  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING SICKLE CELL DISEASE
    Publication number: 20170314015
    Abstract: CRISPR/CAS-related compositions and methods for treatment of Sickle Cell Disease (SCD) are disclosed.
    Type: Application
    Filed: March 26, 2015
    Publication date: November 2, 2017
    Inventors: Ari E. FRIEDLAND, Morgan L. MAEDER, G. Grant WELSTEAD, David A. BUMCROT
  • CRISPR-CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS FOR CANCER IMMUNOTHERAPY
    Publication number: 20170175128
    Abstract: CRISPR/Cas-related composition and methods for treatment of cancer, in particular by using gRNA molecules comprising a targeting domain which is complementary with a target domain from the FAS, BID, CTLA4, PDCD1, CBLB, PTPN6, TRAC or TRBC gene. In some embodiments, gRNAs are used with Cas9 enzymes to cause a cleavage event in said genes within engineered chimeric antigen receptor (CAR) T cells. In some embodiments, CAR T cells are modified to reduce, decrease or repress expression of said genes using gRNAs and Cas9 enzymes; said modified CAR T-cells are meant for therapeutic uses, especially for cancer.
    Type: Application
    Filed: April 17, 2015
    Publication date: June 22, 2017
    Inventors: G. Grant WELSTEAD, Ari E. FRIEDLAND, Morgan L. MAEDER, David A. BUMCROT
  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HERPES SIMPLEX VIRUS TYPE 1 (HSV-1)
    Publication number: 20170073685
    Abstract: CRISPR/CAS-related compositions and methods for treatment of HSV-1 are disclosed.
    Type: Application
    Filed: September 30, 2016
    Publication date: March 16, 2017
    Inventors: Morgan L. Maeder, Ari E. Friedland, Grant G. Welstead, David A. Bumcrot
  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING USHER SYNDROME AND RETINITIS PIGMENTOSA
    Publication number: 20170073674
    Abstract: CRISPR/Cas-related compositions and methods for treatment of Usher Syndrome and/or Retinitis Pigmentosa are disclosed herein.
    Type: Application
    Filed: March 5, 2015
    Publication date: March 16, 2017
    Inventors: Morgan L. MAEDER, David A. BUMCROT
  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING PRIMARY OPEN ANGLE GLAUCOMA
    Publication number: 20170029850
    Abstract: CRISPR/CAS-related compositions and methods for treatment of Primary Open Angle Glaucoma (POAG) are disclosed.
    Type: Application
    Filed: April 1, 2015
    Publication date: February 2, 2017
    Inventors: Morgan L. MAEDER, David A. BUMCROT
  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING CYSTIC FIBROSIS
    Publication number: 20170022507
    Abstract: CRISPR/CAS-related compositions and methods for treatment of Cystic Fibrosis (CF).
    Type: Application
    Filed: October 7, 2016
    Publication date: January 26, 2017
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Deepak Reyon, Morgan L. Maeder, Ari E. Friedland, Grant G. Welstead, David A. Bumcrot
  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HIV INFECTION AND AIDS
    Publication number: 20170007679
    Abstract: CRISPR/CAS-related compositions and methods for treatment of a subject at risk for or having a HIV infection or AIDS are disclosed.
    Type: Application
    Filed: September 23, 2016
    Publication date: January 12, 2017
    Applicant: EDITAS MEDICINE INC.
    Inventors: Morgan L. Maeder, Ari E. Friedland, G. Grant Welstead, David A. Bumcrot
  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING LEBER'S CONGENITAL AMAUROSIS 10 (LCA10)
    Publication number: 20150252358
    Abstract: CRISPR/CAS-related compositions and methods for treatment of Leber's Congenital Amaurosis 10 (LCA10) are disclosed.
    Type: Application
    Filed: March 10, 2015
    Publication date: September 10, 2015
    Inventors: Morgan L. Maeder, David A. Bumcrot, Shen Shen